Platelet aggregation is inhibited by a nitric oxide-like factor released from human neutrophils in vitro
- 1 April 1991
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 77 (4) , 539-545
- https://doi.org/10.1111/j.1365-2141.1991.tb08623.x
Abstract
Summary. Thrombin-induced platelet aggregation was inhibited in vitro by washed human neutrophils. Aggregation was inhibited in a neutrophil concentration dependent manner but glutaraldehyde fixed neutrophils had no significant effect on platelet aggregation. The neutrophil-derived inhibitory factor had the pharmacological profile of nitric oxide. Its action was potentiated by both superoxide dismutase and M&B22, 948, a selective cyclic guanosine mono-phosphate (cyclic GMP) phosphodiesterase inhibitor. Haemoglobin lessened this inhibitory action of neutrophils. L-Arginine, the substrate for nitric oxide formation, enhanced inhibition, whereas, manavanine, a structural analogue of L-arginine, prevented it. Nitric oxide release by neutrophils antagonized platelet ATP secretion and thromboxane B2 release. Inhibition was mediated by nitric oxide activation of guanylate cyclase with a subsequent rise in cyclic GMP. When neutrophils were stimulated with formyl-met-leuphe, there was a further increase in platelet cyclic GMP. This was enhanced by superoxide dismutase, but lessened by haemoglobin. Leukotriene B4 stimulation of neutrophils promoted inhibition of platelet aggregation. Leukotriene B4 alone had no direct effect on thrombin-induced aggregation of platelets. Platelets, when incubated with neutrophils and stimulated with calcium ionophore A23187, increased leukotriene B4 production by neutrophils in a platelet concentration dependent manner. Platelets alone were unable to release leukotriene B4. The action of platelets in haemostasis is modified as they come into contact with neutrophils. This may be an important physiological mechanism.Keywords
This publication has 23 references indexed in Scilit:
- Biological actions and properties of endothelium-derived nitric oxide formed and released from artery and vein.Circulation Research, 1989
- Human red blood cells inhibit endothelium-derived relaxing factor (EDRF) activityEuropean Journal of Pharmacology, 1989
- Generation of nitric oxide by human neutrophilsBiochemical and Biophysical Research Communications, 1989
- Formation and release of nitric oxide from human neutrophils and HL‐60 cells induced by a chemotactic peptide, platelet activating factor and leukotriene B4FEBS Letters, 1989
- Vascular endothelial cells synthesize nitric oxide from L-arginineNature, 1988
- ENDOGENOUS NITRIC OXIDE INHIBITS HUMAN PLATELET ADHESION TO VASCULAR ENDOTHELIUMPublished by Elsevier ,1987
- Macrophage Cytotoxicity: Role for L-Arginine Deiminase and Imino Nitrogen Oxidation to NitriteScience, 1987
- Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factorNature, 1986
- The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholineNature, 1980
- An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregationNature, 1976